Table 2. TP53 and CDKN2A mutations.

N	Diag.	Gene	Mut.	Changed		DBD	Func.	MSKCC impact	FATHMM Impact
				DNA	amino acid
5	DL	TP53	N	c.586C>T	p.R196	+	LOF	NA	Onco./ Cancer
11	HBS NOS	TP53	M	c.738G>A	p.M246I	+	LOF	Med.	Onco./ Cancer
16	DL	TP53	M	c.818G>A	p.R273H	+	LOF	Med.	Onco./ Cancer
28	HBL DH	TP53	M	c.417G>T c.700T>G	p.K139N p.Y234D	+	LOF LOF	Med.	Onco./ Cancer
32	BL	TP53	M	c.843C>A	p.D281E	+	LOF	Med.	Onco./ Cancer
44	DL	TP53	M	c.413C>T	p.A138V	+	LOF	Med.	Onco./ Cancer
52	DL	TP53	M	c.817C>G	p.R273G	+	LOF	Med.	Onco./ Cancer
58	DL	TP53	M	c.701A>G	p.Y234C	+	LOF	Med.	Onco./ Cancer
62	HBL NOS	TP53	M	c.847C>T	p.R283C	+	LOF	Low	Onco./ Cancer
66	DL	TP53	M	c.542G>C	p.R181P	+	LOF	Med.	Onco./ Cancer
5	DL	CDKN2A	M	c.442G>A	p.A148T	-	LOF?	Med.	Neut./ Cancer
35	BL	CDKN2A	M	c.442G>A	p.A148T	-	LOF?	Med.	Neut./ Cancer
46	DL	CDKN2A	M	c.442G>A	p.A148T	-	LOF?	Med.	Neut./ Cancer
66	DL	CDKN2A	M	c.442G>A	p.A148T	-	LOF?	Med.	Neut./ Cancer

N: case number, Diag: diagnosis, DL: diffuse large B-cell lymphoma, HBL NOS: high-grade B-cell lymphoma not otherwise specified, HBL DH: high-grade B-cell lymphoma double hit, BL: Burkitt lymphoma, Mut: mutational type, N: nonsense mutation, M: missense mutation, DBD: DNA-binding region, Func: function, LOF: loss of function, NA: not available, Med: medium impact, Onco: oncogenic impact, Neut: neutral impact, Cancer: cancer-associated variant